Medindia

X

Savient Pharmaceuticals to Hold Second Quarter 2010 Results Conference Call on Wednesday, August 4, 2010

Thursday, July 29, 2010 Drug News J E 4
Advertisement


EAST BRUNSWICK, N.J., July 28 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the second quarter 2010 following the close of the market on Tuesday, August 3, 2010.

Paul Hamelin, President, and David Gionco, Group Vice President, Chief Financial Officer & Treasurer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on August 4, 2010 to discuss these results and to answer questions.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 90977066. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on August 4, 2010 through 11:59 p.m. Eastern Time on August 18, 2010 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 90977066.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as PuricaseŽ, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies OxandrinŽ (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

SVNT-I

SOURCE Savient Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
AMN Healthcare to Acquire Medfinders
S
Express Scripts' Strong Operating Fundamentals Dri...